A new approach with LLT for very-high and extremely-high risk patients

Media formats available:

Preventive PCI versus only optimal medical therapy for vulnerable plaques
Preventive PCI versus only optimal medical therapy for vulnerable plaques
ACC.24
Preventive PCI versus only optimal medical therapy for vulnerable plaques
- Marc Bonaca, MD
Self-assessment on statin eligibility without prescription using a web app
Self-assessment on statin eligibility without prescription using a web app
ACC.24
Self-assessment on statin eligibility without prescription using a web app
- Steven Nissen, MD
More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
ACC.24
More than 70% lowering of triglycerides with APOC3 RNAi in patients with severe hypertriglyceridemia
- Daniel Gaudet, MD, PhD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
ACC.24
Early aggressive lipid-lowering strategy with PCSK9 siRNA performs better than usual care in US patients with ASCVD
- Michael Koren, MD

PACE-CME